NOX4 and primary biliary cholangitis: A placebo-controlled double-blind clinical trial is currently recruiting a projected 318 patients with PBC and will include an initial 52-week period in which Setanaxib, an experimental inhibitor of NOX1 and NOX4, will be administered, followed by a 52-week extension period.